U.S. firms pursue stem-cell research plans-WSJ

	Tweet

Some large companies in the United States are pursuing plans to study stem cells drawn from early stage human embryos, The Wall Street Journal reported on Tuesday, thrusting them into the heated debate over the controversial branch of drug research.

Companies that have initiated research programmes or have plans to are Becton, Dickinson & Co., Invitrogen Corp., Johnson & Johnson, General Electric Co. and the U.S.-based research operations of Swiss drug giant Novartis AG, the Journal said.

None of those companies immediately returned calls for comment.

Stem-cell research has been encouraged by patients with chronic ailments who hope the research leads to ways to replace cells damaged by diseases such as Diabetes and Parkinson’s. Opponents call the research immoral because it requires the destruction of early stage human embryos, most often obtained from fertility clinics.

Starting in August 2001, the Bush administration permitted federal funding for studies using embryonic stem cells, but it restricted support to supplies already taken from embryos at the time. 

RELATED STORIES:
Candles spark a growing number of fires in U.S.   Most US doctors plan to get flu shots - survey   Doctors dispute Blues discount   Republicans to meet on key senator’s asbestos bid   No medical malpractice caps for now   When there’s no place like home for working out   Vietnam to slaughter poultry in big cities   Some Lyme disease Web sites misinform - study   Poor Neighborhoods Create Health “Double Jeopardy” for Minority Kids   US House Democrat says still short on health votes   U.S. uninsured health care cost put at $125 billion   Fears grow over asbestos at Paris tourist site

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]